Gene · 25939
Papers2,857
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,857
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| IMPDH inhibition enhances cytarabine efficacy in SAMHD1-expressing leukaemia cells via guanine nucleotide depletion. | Mol Oncol | 2026 | 41711315 | PubTator, text mining | PubMed |
| The Emerging Role of Interleukin-32 in HIV-Associated Cardiovascular Comorbidities: A Mini Review. | Int J Gen Med | 2026 | 41710575 | PubTator, text mining | PubMed |
| Monocyte-macrophage SAMHD1 alleviates EAMG by modulating the cGAS-STING pathway. | J Neuroinflammation | 2026 | 41709234 | PubTator, text mining | PubMed |
| Aicardi-Goutières Syndrome caused by SAMHD1 mutation: Pathogenesis and Beyond. | Clin Immunol | 2026 | 41666947 | PubTator, text mining | PubMed |
| Ultrarare Variants in DNA Damage Repair and Mitochondrial Genes in Pediatric Acute-Onset Neuropsychiatric Syndrome and Acute Behavioral Regression in Neurodevelopmental Disorders. | Dev Neurosci | 2026 | 41662332 | PubTator, text mining | PubMed |
| Host restriction factor SAMHD1 does not restrict seasonal influenza virus replication in human epithelial or macrophage-like cells. | Virol J | 2026 | 41618306 | PubTator, text mining | PubMed |
| Allosteric targeting with antiviral nucleotide analogs allows fine-tuning of SAMHD1 dNTPase activity. | J Biol Chem | 2026 | 41617034 | PubTator, text mining | PubMed |
| SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication. | J Immunother Cancer | 2026 | 41611242 | PubTator, text mining | PubMed |
| Food deprivation enhances disease resistance: Underlying mechanisms in oysters confronted with pacific oyster mortality syndrome. | iScience | 2026 | 41541659 | PubTator, text mining | PubMed |
| HIV-1 derived oligonucleotides induce a type I IFN/STING dependent immune suppression reversible by targeting IFNARI. | PLoS Pathog | 2026 | 41529066 | PubTator, text mining | PubMed |
| Mechanisms of cellular senescence combined with molecular docking strategies: A biomarker study of potential therapeutic targets for allergic rhinitis. | PLoS One | 2026 | 41511918 | PubTator, text mining | PubMed |
| One mutation, divergent journeys: expanding the clinical spectrum of homozygous SAMHD1 deficiency in childhood. | Rheumatology (Oxford) | 2026 | 41496005 | PubTator, text mining | PubMed |
| Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia. | Cell Cycle | 2026 | 41399259 | PubTator, text mining | PubMed |
| Leveraging protein language models to identify complex trait associations with previously inaccessible classes of functional rare variants. | Cell Genom | 2026 | 41265447 | PubTator, text mining | PubMed |
| Ligandability assessment of interferonopathy-associated proteins using chemoproteomics. | Br J Pharmacol | 2026 | 41225729 | PubTator, text mining | PubMed |
| Somatic variants and frequencies of familial myeloma germline predisposition genes among patients within the CoMMpass dataset. | Expert Rev Hematol | 2026 | 40996854 | PubTator, text mining | PubMed |
| Molecular Mechanisms of Proliferative Senescence and Genomic Instability in Werner Syndrome and the WRN Gene Network. | Cytogenet Genome Res | 2026 | 40971347 | PubTator, text mining | PubMed |
| The Role of SAMHD1 in Viral Resistance and Transduction Efficiency Challenges in Pediatric Hematological Malignancies: Mechanistic Insights and Clinical Perspectives. | Eur J Haematol | 2026 | 40960339 | PubTator, text mining | PubMed |
| Continuous assay for the dNTP triphosphohydrolase of activated SAMHD1. | Anal Biochem | 2026 | 40902696 | PubTator, text mining | PubMed |
| Molecular and Cellular Mechanisms Underlying Neurological and Neuropsychological Manifestations of COVID-19. | Innov Clin Neurosci | 2025 | 41647062 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25939/papers?page=3